In the present study, we evaluated the efficacy of DNLAs extract DDB on improving cognitive function, neuronal and synaptic efficacy, and the degradation of APP/tau products in the triple-transgenic mouse model of Alzheimer’s disease (3 × Tg-AD), which expresses mutant human APP, presenilin, and tau proteins. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.